title: The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.
abstract: Few pharmacological intervention studies have examined the impact of medication on social cognition, particularly emotion perception. The goal of this randomized, double-blind study is to compare the effects of several second generation antipsychotics and a first generation antipsychotic, perphenazine, on emotion perception in individuals with schizophrenia. Patients were assigned to receive treatment with olanzapine, queitapine fumarate, risperidone, ziprasidone or perphenazine for up to 18 months. Eight hundred and seventy three patients completed an emotion perception test immediately prior to randomization and after 2 months of treatment. We also examined baseline predictors of emotion perception change. Most treatments were associated with a small, non-statistically significant improvement in emotion perception at two months, although they did not differ from one another. Greater improvement in emotion perception at 2 months was significantly predicted by lower baseline emotion perception and higher baseline neurocognitive functioning, and marginally predicted by less time on an antipsychotic.
authors.affiliation: University of North Carolina-Chapel Hill, Department of Psychology, Davie Hall, Chapel Hill, NC 27599-3270, USA. dpenn@email.unc.edu
authors.forename: David L
authors.initials: DL
authors.lastname: Penn
authors.forename: Richard S E
authors.initials: RS
authors.lastname: Keefe
authors.forename: Sonia M
authors.initials: SM
authors.lastname: Davis
authors.forename: Piper S
authors.initials: PS
authors.lastname: Meyer
authors.forename: Diana O
authors.initials: DO
authors.lastname: Perkins
authors.forename: Diane
authors.initials: D
authors.lastname: Losardo
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Lieberman
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004644:Emotions / Q000187:drug effects*; D005145:Face; D005149:Facial Expression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000188:drug therapy* / Q000209:etiology; D009483:Neuropsychological Tests; D010546:Perphenazine / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D012189:Retrospective Studies; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy; D012565:Schizophrenic Psychology; D016896:Treatment Outcome; D014796:Visual Perception / Q000187:drug effects; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D010546:Perphenazine